China Approves First Bispecific ADC for Nasopharyngeal Cancer: What It Means for Patients and Drug Development
China’s National Medical Products Administration (NMPA) has approved Iza-bren (BL-B01D1), a first-in-class bispecific antibody-drug conjugate (ADC), for treating recurrent or metastatic nasopharyngeal carcinoma (NPC) after failure of platinum chemotherapy and PD-1/PD-L1 inhibitor therapy. Developed by SystImmune and its parent company Sichuan Biokin Pharmaceutical, this approval marks a significant milestone in oncology, offering a new treatment option for a disease with limited therapeutic alternatives.
Why This Approval Matters for NPC Patients
Nasopharyngeal carcinoma, a rare but aggressive cancer primarily found in southern China, Southeast Asia, and parts of North Africa, has historically relied on chemotherapy and immunotherapy as standard treatments. However, for patients whose disease progresses after these therapies, options become scarce, with median overall survival rates below one year.
The approval of Iza-bren introduces a novel mechanism: a bispecific ADC that targets EGFR (Epidermal Growth Factor Receptor) and HER3 (Human Epidermal Growth Factor Receptor 3)—two proteins overexpressed in many cancers, including NPC. By binding to both targets, the drug delivers a Topo1 inhibitor payload directly into cancer cells, inducing cytotoxic stress and cell death.
Key clinical data from the pivotal Phase III BL-B01D1-303 trial:
- Confirmed objective response rate (ORR): 54.6% (vs. 27.0% for physician’s choice chemotherapy)
- Median duration of response: 8.5 months (vs. 4.8 months for chemotherapy)
- Median progression-free survival (PFS): 8.38 months (vs. 4.34 months for chemotherapy)
"This approval is a game-changer for NPC patients who have exhausted standard therapies," says Dr. Li Jianjun, an oncologist at Shanghai Cancer Center, who was not involved in the trial. "The dual-targeting mechanism of Iza-bren provides a more precise and potent approach compared to traditional ADCs or monoclonal antibodies."
How Bispecific ADCs Differ from Traditional Cancer Therapies
Traditional monoclonal antibodies (mAbs) like PD-1/PD-L1 inhibitors work by blocking immune checkpoints, while ADCs combine an antibody with a cytotoxic drug to deliver it directly to cancer cells. However, bispecific ADCs take this further by targeting two distinct proteins, enhancing tumor selectivity and reducing off-target toxicity.
Iza-bren’s mechanism is particularly promising because EGFR and HER3 are frequently co-expressed in NPC and other epithelial cancers, including breast, lung, and colorectal cancers. This suggests potential for broader applications beyond NPC.
"The approval of Iza-bren validates the therapeutic potential of bispecific ADCs in oncology," says Dr. Wang Xiaofeng, Chief Medical Officer at SystImmune. "We are now exploring its use in other solid tumors where EGFR and HER3 are overexpressed."
Global Implications: A New Standard for ADC Development
While Iza-bren’s approval is China’s first for a bispecific ADC, it aligns with a growing trend in global oncology drug development. Companies like Bristol Myers Squibb (BMS), which is partnering with SystImmune and Biokin on iza-bren’s global development, are investing heavily in next-generation ADCs.
Why this matters for the biopharma industry:
- China’s ADC Sector is Accelerating – The country has rapidly become a leader in ADC innovation, with over 100 ADC programs in development, according to China Biopharma Association (CBA).
- Bispecific ADCs Are the Future – Unlike traditional ADCs (e.g., trastuzumab deruxtecan for breast cancer), bispecific designs allow for dual-targeting precision, potentially improving efficacy and reducing resistance.
- Global Partnerships Are Key – The collaboration between SystImmune, Biokin, and BMS shows how Chinese biotech firms are leveraging international partnerships to bring novel therapies to market faster.
"China’s approval of Iza-bren is a testament to the country’s growing influence in biopharma R&D," says Dr. Sarah Carlson, Head of Oncology at McKinsey & Company. "This could set a precedent for how bispecific ADCs are developed and approved in other regions, particularly for rare and aggressive cancers."
What Happens Next? Clinical Trials and Broader Applications
While Iza-bren is currently approved only in China, its developers are preparing for global regulatory submissions, including with the U.S. FDA and European Medicines Agency (EMA).
Potential next steps:
- Phase III trials in other cancers (e.g., breast, lung, and head & neck cancers) where EGFR/HER3 co-expression is high.
- Combination therapies – Testing Iza-bren with immunotherapies (e.g., PD-1 inhibitors) to enhance anti-tumor responses.
- Expanding ADC platforms – SystImmune and Biokin are developing additional bispecific ADCs using their brengitecan-based platform, which could unlock new treatment options for other hard-to-treat cancers.
Challenges and Considerations
Despite its promise, bispecific ADCs face hurdles:
- Manufacturing complexity – Producing dual-targeting antibodies requires advanced bioprocessing techniques.
- Cost and accessibility – If priced high, these therapies may not be widely available in low-income regions where NPC is most common.
- Resistance mechanisms – Like all targeted therapies, tumor heterogeneity could lead to resistance over time.
"While Iza-bren is a major breakthrough, long-term success will depend on overcoming these challenges," says Dr. Chen Wei, a cancer researcher at Peking University. "If the drug proves effective in broader cancer types, it could redefine treatment paradigms."
FAQ: What Patients and Investors Need to Know About Iza-bren
1. Who is Iza-bren approved for?
Iza-bren is approved for adult patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) who have progressed after platinum-based chemotherapy and PD-1/PD-L1 inhibitor therapy.
2. How does Iza-bren work differently from existing NPC treatments?
Unlike chemotherapy (e.g., cisplatin, gemcitabine) or immunotherapies (e.g., pembrolizumab, nivolumab), Iza-bren is a bispecific ADC that:
- Targets EGFR and HER3 simultaneously (both overexpressed in NPC).
- Delivers a Topo1 inhibitor payload directly into cancer cells, causing cell death.
- Avoids the immune-related side effects seen with PD-1 inhibitors (e.g., pneumonitis, colitis).
3. What were the key results from the Phase III trial?
The BL-B01D1-303 trial showed:
- 54.6% objective response rate (ORR) vs. 27.0% for chemotherapy.
- 8.5-month median duration of response vs. 4.8 months.
- 8.38-month median progression-free survival (PFS) vs. 4.34 months.
4. Is Iza-bren available outside China?
Not yet. The approval is China-specific, but SystImmune and BMS are preparing for global submissions (FDA, EMA) in the coming years.
5. Could Iza-bren work for other cancers?
Yes. EGFR and HER3 are co-expressed in multiple cancers, including:
- Breast cancer (HER2-positive and triple-negative)
- Lung cancer (non-small cell and EGFR-mutant)
- Colorectal cancer
Clinical trials are underway to explore these applications.
6. What are the potential side effects?
Common side effects reported in trials include:
- Fatigue
- Nausea/vomiting
- Peripheral neuropathy (nerve damage, common with Topo1 inhibitors)
- Skin reactions (due to EGFR targeting)
"Monitoring and dose adjustments will be critical," says Dr. Li, "but the safety profile appears manageable compared to chemotherapy."
7. How does this approval compare to other ADC approvals?
| Drug | Target | Indication | Approval Year | Response Rate |
|---|---|---|---|---|
| Trastuzumab deruxtecan (Enhertu) | HER2 | Breast, gastric cancer | 2022 (US) | ~60% |
| Sacituzumab govitecan (Trodelvy) | TROP2 | Breast, ovarian cancer | 2021 (US) | ~30% |
| Iza-bren (BL-B01D1) | EGFR + HER3 | Nasopharyngeal cancer | 2026 (China) | 54.6% |
"Iza-bren’s 54.6% ORR is among the highest seen in late-stage NPC trials," notes Dr. Carlson. "This suggests it could become a new standard of care."
8. What’s next for SystImmune and Biokin?
- Global regulatory filings (FDA, EMA) for Iza-bren.
- Expansion into other cancers (breast, lung, colorectal).
- Development of additional bispecific ADCs using their brengitecan platform.
Did You Know?
✅ Nasopharyngeal carcinoma (NPC) is rare globally but endemic in southern China, with over 100,000 new cases annually in Asia.
✅ Bispecific ADCs are a fast-growing class—15+ are in late-stage trials, per BioWorld Data.
✅ China is now a leader in ADC innovation, with over 100 programs in development—more than the U.S. and EU combined.
Pro Tip for Investors: Watch These Key Developments
- FDA/EMA submissions (expected 2027–2028).
- Phase III trial expansion into other cancers.
- Partnerships with global pharma (e.g., BMS’s role in commercialization).
Final Thought: A New Era for Cancer Treatment?
Iza-bren’s approval is more than just a win for NPC patients—it signals a shift in how cancers are treated. Bispecific ADCs represent the next frontier in precision oncology, offering higher efficacy and lower toxicity than traditional therapies.
"This is just the beginning," says Dr. Wang. "If successful in broader indications, bispecific ADCs could redefine cancer care—just as monoclonal antibodies did two decades ago."
Want to stay updated on ADC breakthroughs? Subscribe to our biotech newsletter or explore more in our Oncology Innovations section. Have questions? Drop them in the comments—we’d love to hear your thoughts!
Worth a look